You just read:

Once-Daily Oral Anticoagulant LIXIANA® (edoxaban) Met Primary Endpoint in Investigational Hokusai-VTE CANCER Study

News provided by

Servier Canada Inc.

Dec 15, 2017, 08:00 ET